Rob Hopfner
Managing Partner at Pivotal bioVenture Partners
San Francisco, California
Overview
Work Experience
Managing Partner
2017 - Current
- Life sciences venture capital firm focused on North American and European biotech - Built team and operations, and co-led investment, fundraising, and LP management activities in two biotech venture capital funds totaling $689 million under management Key investments include: - Arcutis Therapeutics (NASDAQ: ARQT), Evommune, Inc, Exscientia, Inc (acquired by Recursion), Gracell Therapeutics (acquired by Astra Zeneca), Karuna Therapeutics (acquired by BMS), Oculis Therapeutics (NASDAQ: OCS), Vaxcyte Therapeutics (NASDAQ: PCVX)
Executive Committee Member
2022
Oversight of public investment, VC fund investments, and Pivotal bioVenture Partners investment activities
Board Member
2020
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Raised $268,000,000.00 from NEXTBio Capital, RTW Investments, Longwood Fund, RA Capital Management, Sectoral Asset Management, Marshall Wace, Avego Bioscience Capital, SymBiosis, FemHealth Ventures and Andera Partners.
Board Member
2021
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Raised $165,000,000.00 from CRV, RA Capital Management, Pappas Capital, DCVC Bio, SoftBank Vision Fund, Pivotal bioVenture Partners, M Ventures, Surveyor Capital, Lux Capital and Neotribe Ventures.
Board Member
2019
Board Member
2017 - 2023
Board Member
2017 - 2021
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Raised $3,847,040,000.00 from CARB-X and CARB-X.
Managing Director and Partner
2009 - 2017
Life sciences venture capital firm focused on North American and European biotech Led or co-led 12 investments as a Partner at the firm with top-tier returns and low loss-rate Key investments include: - Civitas Therapeutics (acquired by Acorda), Dermira (acquired by Lilly), Hyperion Therapeutics (acquired by Horizon Pharma), Madrigal Pharmaceuticals (NASDAQ: MDGL), Merus Therapeutics (NASDAQ: MRUS), NextWave Pharmaceuticals (acquired by Pfizer), Protez (acquired by Novartis), Vtesse (acquired by Sucampo), and Zymogenetics (acquired by BMS)
Principal
2006 - 2009
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Board Member
2015 - 2017
Rare disease company acquired by Sucampo Therapeutics
Board Member
2013 - 2014
Board Observer
2010 - 2014
Dermatology drug development company acquired by Lilly, Inc.